论文部分内容阅读
目的评价贝那普利治疗中国原发性高血压患者的疗效与安全性。方法全面检索PubMed、Embase、Cochrane、CBM、CNKI等数据库中1989-01-2010-12期间发表的相关研究,由2位研究者根据纳入和排除标准,独立选择符合标准的随机对照试验(RCT),并提取相关数据。采用Stata11软件进行统计分析。结果 34项试验符合纳入标准,共1503例原发性高血压患者应用贝那普利,剂量范围10～40mg/d。贝那普利单药治疗可降低患者收缩压24.4mmHg(95% CI21.7～27.1,P<0.01),舒张压15.7mmHg(95% CI14.2～17.1,P<0.01)。与钙拮抗剂相比,贝那普利降低收缩压的幅度略小3.4mmHg(P=0.08),而舒张压降低幅度相似(P=0.55)。贝那普利收缩压(P=0.58)和舒张压(P=0.43)的降低幅度与血管紧张素受体拮抗剂(ARB)相似。咳嗽是贝那普利治疗的主要不良事件,发生率为10.6%。血管性水肿罕见(0.2%)。结论贝那普利治疗中国原发性高血压患者安全有效。
Objective To evaluate the efficacy and safety of benazepril in the treatment of patients with essential hypertension in China. Methods A comprehensive study of published data from PubMed, Embase, Cochrane, CBM, CNKI and other databases published between January 1989 and December 2010 was conducted. Two randomized controlled trials (RCTs) were randomly selected according to inclusion and exclusion criteria by two investigators. , And extract the relevant data. Stata11 software for statistical analysis. Results 34 trials met the inclusion criteria, and a total of 1503 patients with essential hypertension were benazepril. The dose range was 10-40 mg / d. Benazepril monotherapy reduced the systolic blood pressure by 24.4mmHg (95% CI 21.7-27.1, P <0.01) and diastolic blood pressure 15.7mmHg (95% CI 14.2-17.1, P <0.01). Compared with calcium antagonists, benazepril reduced systolic blood pressure by slightly less than 3.4 mmHg (P = 0.08), while diastolic blood pressure decreased similarly (P = 0.55). The decrease of benazepril systolic blood pressure (P = 0.58) and diastolic blood pressure (P = 0.43) was similar to that of angiotensin receptor blocker (ARB). Cough is the major adverse event of benazepril treatment, with a rate of 10.6%. Vascular edema is rare (0.2%). Conclusion Benazepril is safe and effective in treating patients with essential hypertension in China.